Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Mylan Inc    MYL   US6285301072

MYLAN INC (MYL)

66
Delayed Quote. Delayed Nasdaq - 11/21 04:00:01 pm
55.79 USD   +1.03%
2d ago MYLAN : Earnings Highlights - Mylan
11/14 MYLAN : Launches Generic Loestrin 24 Fe®
11/14 MYLAN : Signs Strategic Alliance Agreement with Walt Disney Parks and Resor..
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/17/2014 11/18/2014 11/19/2014 11/20/2014 11/21/2014 Date
55.13(c) 56.24(c) 55.68(c) 55.22(c) 55.79(c) Last
4 017 413 4 137 823 4 250 249 1 861 963 2 628 164 Volume
+2.00% +2.01% -1.00% -0.83% +1.03% Change
More quotes
Company
Mylan, Inc. is a generic and specialty pharmaceuticals company, through its subsidiaries, which develops, manufactures, markets and distributes pharmaceuticals.The company operates its business through two segments: Generics & Specialty.The Generics segment primarily develops, manufactures, sells... 
Sector
Pharmaceuticals
Calendar
02/26Earnings Release
Surperformance© rating of Mylan Inc
Trading Rating : Investor Rating :
More about the company
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | MYL | US6285301072 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 7 709 M
EBIT 2014 1 981 M
Net income 2014 1 182 M
Debt 2014 7 430 M
Yield 2014 -
Sales 2015 9 985 M
EBIT 2015 2 766 M
Net income 2015 1 958 M
Debt 2015 6 332 M
Yield 2015 -
PER 2014 19,52
PER 2015 15,01
EV / Sales 2014 3,64x
EV / Sales 2015 2,70x
Capitalization 20 667 M
More Financials
Latest news on MYLAN INC
2d ago MYLAN : Earnings Highlights - Mylan
11/14 MYLAN : Launches Generic Viramune XR®
11/14 MYLAN : Third Quarter 2014 Adjusted Diluted EPS Increases 41% to $1.16
11/14 MYLAN : Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to..
11/14 MYLAN : Launches Generic Loestrin 24 Fe®
11/14 MYLAN : EpiPen4Schools® Program Enhances Support of National Movement to Improve..
11/12 MYLAN : Launches Generic Loestrin 24 Fe®
11/07 MYLAN : Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to..
11/05 MEDICINES : Wins Favorable Judgment in Angiomax® Bivalirudin Patent Litigation
11/05 MYLAN : Launches Generic Viramune XR®
11/05 MYLAN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
11/05 MYLAN : Launches Generic Loestrin 24 Fe®
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF